Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on Tuesday, March 4, 2025, at 8:30 a.m. ET to review the company's fourth quarter and full year 2024 financial results and provide business updates.
The clinical-stage biotechnology company, which focuses on RNA medicines to transform human health, will make the webcast accessible through the "Investor Events" section of their website at https://ir.wavelifesciences.com/events-publications/events.
Analysts who wish to participate in the Q&A portion can join via an audio conferencing link that will provide dial-in information upon registration. An archived version of the webcast will be available on the company's website following the live event.
Wave Life Sciences (Nasdaq: WVE) ha annunciato che ospiterà un webcast e una conferenza telefonica dal vivo il martedì 4 marzo 2025 alle 8:30 a.m. ET per rivedere i risultati finanziari del quarto trimestre e dell'intero anno 2024 e fornire aggiornamenti aziendali.
La società biotecnologica in fase clinica, che si concentra sui farmaci a base di RNA per trasformare la salute umana, renderà il webcast accessibile attraverso la sezione
Wave Life Sciences (Nasdaq: WVE) ha anunciado que llevará a cabo un webcast en vivo y una conferencia telefónica el martes 4 de marzo de 2025 a las 8:30 a.m. ET para revisar los resultados financieros del cuarto trimestre y del año completo 2024 y proporcionar actualizaciones sobre el negocio.
La empresa de biotecnología en etapa clínica, que se centra en medicamentos de ARN para transformar la salud humana, hará que el webcast esté accesible a través de la sección
Wave Life Sciences (Nasdaq: WVE)는 2025년 3월 4일 화요일 오전 8시 30분 ET에 2024년 4분기 및 연간 재무 결과를 검토하고 비즈니스 업데이트를 제공하기 위해 라이브 웹캐스트 및 컨퍼런스 콜을 개최한다고 발표했습니다.
RNA 의약품을 통해 인류 건강을 변화시키는 데 중점을 둔 임상 단계 생명공학 회사는 웹캐스트를 https://ir.wavelifesciences.com/events-publications/events의
Wave Life Sciences (Nasdaq: WVE) a annoncé qu'elle organisera un webcast en direct et une conférence téléphonique le mardi 4 mars 2025 à 8h30 ET pour examiner les résultats financiers du quatrième trimestre et de l'année entière 2024 et fournir des mises à jour sur l'entreprise.
La société de biotechnologie en phase clinique, qui se concentre sur les médicaments à base d'ARN pour transformer la santé humaine, rendra le webcast accessible via la section
Wave Life Sciences (Nasdaq: WVE) hat angekündigt, dass am Dienstag, den 4. März 2025 um 8:30 Uhr ET ein Live-Webcast und eine Telefonkonferenz stattfinden werden, um die Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 zu überprüfen und Unternehmensupdates bereitzustellen.
Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf RNA-Medikamente zur Transformation der menschlichen Gesundheit konzentriert, wird den Webcast über den Bereich
- None.
- None.
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company’s fourth quarter and full year 2024 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and Obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
FAQ
When will Wave Life Sciences (WVE) release its Q4 and full year 2024 financial results?
How can investors access Wave Life Sciences' (WVE) Q4 2024 earnings call?
What will be discussed during Wave Life Sciences' (WVE) March 4, 2025 conference call?
Will Wave Life Sciences (WVE) provide a recording of their Q4 2024 earnings call?
